Table 1.
HLA-matched sibling transplant: patient, disease and transplant characteristics
| Characteristic | No G-CSF | G-CSF | P value |
|---|---|---|---|
| No. of patients | 1174 | 313 | |
| Age, years | 0.47 | ||
| 18- 30 | 113 (10%) | 26 (8%) | |
| 31- 40 | 127 (11%) | 25 (8%) | |
| 41- 50 | 240 (20%) | 61 (19%) | |
| 51- 60 | 381 (32%) | 118 (38%) | |
| 61- 70 | 283 (24%) | 75 (24%) | |
| > 70 | 30 (3%) | 8 (3%) | |
| Gender | 0.04 | ||
| Male | 649 (55%) | 193 (62%) | |
| Female | 525 (45%) | 120 (38%) | |
| Race | < 0.001 | ||
| Caucasian | 1023 (87%) | 252 (81%) | |
| African American | 48 (4%) | 29 (9%) | |
| Asian and other races | 103 (9%) | 32 (10%) | |
| Ethnicity | 0.21 | ||
| Non-Hispanic | 1019 (87%) | 263 (84%) | |
| Hispanic | 155 (13%) | 50 (16%) | |
| Performance score | 0.25 | ||
| 90-100 | 709 (60) | 177 (57%) | |
| <90 | 465 (40) | 136 (43%) | |
| Hematopoietic cell transplantation- comorbidity index | 0.59 | ||
| 0-2 | 680 (58%) | 176 (56%) | |
| 3+ | 494 (42%) | 137 (44%) | |
| Donor-recipient cytomegalovirus serostatus | 0.86 | ||
| Positive / Positive | 478 (41%) | 120 (38%) | |
| Positive / Negative | 156 (13%) | 42 (13%) | |
| Negative / Positive | 292 (25%) | 84 (27%) | |
| Negative / Negative | 248 (21%) | 67 (21%) | |
| Disease | 0.96 | ||
| Acute myeloid leukemia | 636 (54%) | 167 (53%) | |
| Acute lymphoblastic leukemia | 202 (17%) | 55 (18%) | |
| Myelodysplastic syndrome | 336 (29%) | 91 (29%) | |
| Disease risk index | 0.70 | ||
| Low | 58 (5%) | 12 (4%) | |
| Intermediate | 712 (61%) | 190 (61%) | |
| High and Very High | 404 (34%) | 111 (35%) | |
| Time to transplant from diagnosis | 0.40 | ||
| Less than one year | 886 (75%) | 229 (73%) | |
| More than one year | 288 (25%) | 84 (27%) | |
| Conditioning regimen intensity | <0.001 | ||
| Myeloablative, total body irradiation containing | 369 (31%) | 73 (23%) | |
| Myeloablative, non- total body irradiation containing | 406 (35%) | 112 (36%) | |
| Reduced intensity, total body irradiation containing | 70 (6%) | 44 (14%) | |
| Reduced intensity, non- total body irradiation containing | 329 (28%) | 84 (27%) | |
| GVHD prophylaxis | < 0.001 | ||
| Calcineurin inhibitor + mycophenolate | 250 (21%) | 95 (30%) | |
| Calcineurin inhibitor + methotrexate | 715 (61%) | 178 (57%) | |
| Calcineurin inhibitor + other | 209 (18%) | 40 (13%) | |
| Transplant period | 0.37 | ||
| 2007-2011 | 537 (46%) | 152 (49%) | |
| 2011-2016 | 637 (54%) | 161 (51%) | |
| Median follow up in months (Min-Max) | 62.8(3-125) | 70.9 (12-123) |